FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to pharmaceutics and medicine. Object 1 is a dry pharmaceutical formulation containing a CNP conjugate, which contains a CNP fragment which is covalently and reversibly conjugated with a polymer fragment and contains a ring fragment having the amino acid sequence SEQ ID NO: 96, wherein the ring fragment is located between two cysteine residues, which form a disulphide bridge, as well as trehalose dihydrate, succinic acid and Tris. Object 2 is a method of producing a dry pharmaceutical composition. Objects 3 and 4 are the method for reconditioning a dry pharmaceutical composition and a reconstituted pharmaceutical composition. Object 5 is a method of treating or controlling achondroplasia in a patient.
EFFECT: stable long-term storage of the dry pharmaceutical formulation of the CNP conjugate.
17 cl, 12 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CNP PRODRUGS | 2016 |
|
RU2824988C1 |
| CONTROLLED RELEASE COMBINATION THERAPY WITH CNP AGONISTS | 2017 |
|
RU2768747C2 |
| LIQUID PHARMACEUTICAL FORMULATIONS OF PTH CONJUGATES | 2020 |
|
RU2817015C2 |
| TREATMENT OF HYPOPARATHYROIDISM | 2021 |
|
RU2827712C1 |
| PTH COMPOUNDS WITH LOW PEAK-TO-MINIMUM RATIOS | 2017 |
|
RU2766959C2 |
| DOSAGE MODE OF PTH COMPOUND OF CONTROLLED RELEASE | 2017 |
|
RU2777357C2 |
| PRODRUG COMPOSITIONS BASED ON CROSS-LINKED HYALURONIC ACID HYDROGEL AND METHODS OF THEIR PRODUCTION | 2018 |
|
RU2812787C2 |
| USE OF OPTIONS OF NATRIURETIC PEPTIDE OF TYPE C FOR TREATMENT OF OSTEOARTHRITIS | 2016 |
|
RU2759679C2 |
| CONJUGATE OF ANTI-CLAUDIN ANTIBODY AND MEDICINAL AGENT AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2826119C1 |
| SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | 2019 |
|
RU2815199C2 |
